Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities.

Autor:	Shi DD; Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, USA., Guo JA; Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA; School of Medicine, University of California, San Francisco, San Francisco, CA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Biological and Biomedical Sciences Program, Harvard University, Boston, MA, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hoffman HI; Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Harvard-MIT Health Sciences and Technology Program, Harvard Medical School, Boston, MA, USA., Su J; Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Mino-Kenudson M; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Barth JL; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Schenkel JM; Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Loeffler JS; Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Shih HA; Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Hong TS; Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Wo JY; Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Jacks T; Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA., Zheng L; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Wang TC; Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY, USA., Hwang WL; Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Biology, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. Electronic address: whwang1@mgh.harvard.edu.
Jazyk:	angličtina
Zdroj:	The Lancet. Oncology [Lancet Oncol] 2022 Feb; Vol. 23 (2), pp. e62-e74.
DOI:	10.1016/S1470-2045(21)00596-9
Abstrakt:	With increasing attention on the essential roles of the tumour microenvironment in recent years, the nervous system has emerged as a novel and crucial facilitator of cancer growth. In this Review, we describe the foundational, translational, and clinical advances illustrating how nerves contribute to tumour proliferation, stress adaptation, immunomodulation, metastasis, electrical hyperactivity and seizures, and neuropathic pain. Collectively, this expanding knowledge base reveals multiple therapeutic avenues for cancer neuroscience that warrant further exploration in clinical studies. We discuss the available clinical data, including ongoing trials investigating novel agents targeting the tumour-nerve axis, and the therapeutic potential for repurposing existing neuroactive drugs as an anti-cancer approach, particularly in combination with established treatment regimens. Lastly, we discuss the clinical challenges of these treatment strategies and highlight unanswered questions and future directions in the burgeoning field of cancer neuroscience. Competing Interests: Declaration of interests MM-K reports personal fees from H3 Biomedicine and AstraZeneca; grants from Novartis; and royalties from Elsevier, outside the submitted work. TSH reports personal fees from Synthetic Biologics, Novocure, and Merck; equity in PanTher Therapeutics; and grants from Taiho, AstraZeneca, Bristol Myers Squibb, Tesaro, Ipsen, and Puma, outside the submitted work. AJA reports personal fees from Merck, Arrakis Therapeutics, and Oncorus; grants from Mirati Therapeutics, Deerfield, Novo Ventures, National Cancer Institute, Lustgarten Foundation, Pancreatic Cancer Action Network, Doris Duke Charitable Foundation, and Dana-Farber Cancer Institute Hale Center for Pancreatic Cancer Research; and grants and personal fees from Syros Pharmaceuticals, outside the submitted work. TJ reports grants from Lustgarten Foundation; stock in Amgen and Thermo Fisher Scientific; and membership of the Board of Directors of Amgen and Thermo Fisher Scientific, outside the submitted work. LZ reports grants from Merck, during the conduct of the study; and grants from iTeos, Bristol Meyers Squibb, Merck, AstraZeneca, Amgen, NovaRock, Inxmed, and Halozyme; personal fees from Biosion, NovaRock, Akrevia/ Xilio, Datarevive, QED, Natera, Ambrx, Snow Lake Capital, and Tempus; personal fees from Alphamab and Mingruizhiyao; and shares in Alphamab and Mingruizhiyao, outside the submitted work. PYW reports research support from Agios, AstraZeneca/Medimmune, Beigene, Celgene, Eli Lily, Genentech/Roche, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Oncoceutics, Vascular Biogenics, and VBI Vaccines; and membership on the advisory board of Agios, AstraZeneca, Bayer, Boston Pharmaceuticals, CNS Pharmaceuticals, Elevate Bio Immunomic Therapeutics, Imvax, Karyopharm, Merck, Novartis, Nuvation Bio, Vascular Biogenics, VBI Vaccines, and Voyager, outside the submitted work. All other authors declare no competing interests. (Copyright © 2022 Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu